Gain Therapeutics Appoints New CMO and CSO, O'Connell Departs

TL;DR

Gain Therapeutics shakes up leadership, bringing in Ridgeway as CMO and Roth as CSO.

AI Summary

Gain Therapeutics, Inc. announced on April 5, 2024, the appointment of Dr. Marcella R. Ridgeway as Chief Medical Officer and Dr. Jonathan M. Roth as Chief Scientific Officer. The company also reported the departure of Dr. Daniel J. O'Connell as Chief Medical Officer. These changes are effective immediately.

Why It Matters

The appointment of new leadership in key scientific and medical roles suggests a strategic shift or expansion in Gain Therapeutics' research and development efforts, potentially impacting its drug pipeline and future clinical trials.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially in scientific and medical roles, can indicate internal shifts or challenges that may affect the company's strategic direction and operational execution.

Key Players & Entities

• Gain Therapeutics, Inc. (company) — The company filing the report.
• Dr. Marcella R. Ridgeway (person) — Appointed Chief Medical Officer.
• Dr. Jonathan M. Roth (person) — Appointed Chief Scientific Officer.
• Dr. Daniel J. O'Connell (person) — Departed Chief Medical Officer.
• April 5, 2024 (date) — Effective date of appointments and departure.

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value GANX The NASDAQ Stock Marke
• $370,000 — led to receive an annual base salary of $370,000 and is eligible to receive, as determin
• $3.56 — 's common stock at an exercise price of $3.56 per share, vesting over a four year per

Filing Documents

• tm2411246d1_8k.htm (8-K) — 35KB
• tm2411246d1_ex10-1.htm (EX-10.1) — 138KB
• tm2411246d1_ex99-1.htm (EX-99.1) — 18KB
• tm2411246d1_ex99-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-24-044750.txt ( ) — 414KB
• ganx-20240405.xsd (EX-101.SCH) — 3KB
• ganx-20240405_lab.xml (EX-101.LAB) — 33KB
• ganx-20240405_pre.xml (EX-101.PRE) — 22KB
• tm2411246d1_8k_htm.xml (XML) — 4KB

02. Departure of Directors or Certain

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer Appointment On April 5, 2024, Gain Therapeutics, Inc. (the "Company") appointed Gene Mack as its Chief Financial Officer, to be effective as of April 8, 2024 (the "Appointment Date"). In this role, Mr. Mack will also serve as the Company's Principal Financial Officer and as the Company' Secretary, effective as of the Appointment Date. Prior to joining the Company, from October 2021 to October 2023, Mr. Mack, 50, was Chief Financial Officer of Imcyse SA, a privately held biotechnology company engaged in the discovery and development of novel immunotherapeutics targeted at curing sever autoimmune diseases. Prior to Imcyse, from September 2020 to November 2021 Mr. Mack was Chief Financial Officer at OncoC4, Inc., a privately held biotechnology company engaged in the discovery and development of novel immune modulating and immune-oncology therapies that spun out of Merck & Co.'s (MSD) acquisition of OncoImmune, Inc. At the time of the acquisition, Mr. Mack was the Chief Financial Officer of OncoImmune. From May of 2019 to September 2020, Mr. Mack was Chief Financial Officer of BiomUp, USA Inc., privately held biotechnology company engaged in the discovery and development of novel hemostatic agents for use during surgery. From April of 2018 to December of 2018 was Chief Financial at Sellas Lifesciences Group, Inc. (Nasdaq: SLS), where he led Sellas' successful IPO efforts. From April 2015 to April 2018, Mr. Mack was a consultant for a number of private and public biotechnology and pharmaceutical companies providing advisory and support services for raising capital and business development transactions as well as implementing and managing all aspects of corporate finance, accounting, SEC reporting, legal affairs, treasury and investor/public relations. Mr. Mack received both his BS in Bio

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On April 8, 2024, the Company issued a press release announcing the appointment of Mr. Mack as the Company's new Chief Financial Officer. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Employment Agreement, by and between the Company and Gene Mack, effective as of April 8, 2024. 99.1 Press Release, dated April 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. By: /s/ Matthias Alder Name: Matthias Alder Title: Chief Executive Officer Date: April 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR